Dextromethadone - Relmada Therapeutics

Drug Profile

Dextromethadone - Relmada Therapeutics

Alternative Names: +-Methadone - Relmada Therapeutics; 6S-Methadone - Relmada Therapeutics; d Methadone - Relmada Therapeutics; REL 1017; S-Methadone - Relmada Therapeutics

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Relmada Therapeutics
  • Class Analgesics; Drug withdrawal therapies; Ketones
  • Mechanism of Action NMDA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Postherpetic neuralgia
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Neuropathic pain
  • Preclinical Depressive disorders

Most Recent Events

  • 25 Jan 2017 U.S. Food and Drug Administration (FDA) approves IND application for dextromethadone in Depression (Treatment-resistant)
  • 19 Oct 2016 Relmada Therapeutics has patent protection for dextromethadone in USA
  • 27 Jun 2016 Preclinical trials in Depressive disorders in USA (PO) before June 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top